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pass graft surgery. Her medical history revealed coronary ar-
tery disease, a coronary artery bypass graft four years ago,
hypertension, hypothyroidism, a right below-the-knee amputa-
tion two years ago, and a left toe amputation one year ago.
Last year she underwent left femoral-popliteal bypass graft
surgery; during the past four years, she has had recurrent arte-
riovenous graft failure necessitating six additional revasculari-
zation procedures.
Physical examination revealed a slightly obese woman who
was somewhat short of breath at rest but in no apparent distress.
Her temperature was 97.78F; heart rate, 87 beats/min; respira-
tory rate, 18 breaths/min; and blood pressure, 118/78 mm Hg.
No jugular venous distention was present. She had a grade
II/VI systolic ejection murmur. Four toes on her left foot were
gangrenous; a large open ulcer was present. The left dorsalis
pedis pulse was weak.CASE PRESENTATIONS
Her medications included: human insulin (recombinant DNA
Patient 1 origin, Humulin N), 20 units subcutaneously every morning;
A 63-year-old lawyer who had devoted most of his life to calcium acetate, 1320 mg 3 times daily; digoxin, 0.125 mg orally
politics was found at age 50 to have an elevated blood pressure every other day; erythropoietin a, 5000 units subcutaneously
(140/100 mm Hg), left-ventricular hypertrophy, and nonspecific every other day; levothyroxine sodium, 0.75 mg daily; enalapril,
T-wave changes on his electrocardiogram (EKG). He had had 5 mg daily; pravastatin, 20 mg daily; warfarin, 2.5 to 5.0 mg,
typhoid fever at age 30 and poliomyelitis at age 39; the latter as needed to maintain INR at 2.0 to 2.5; and multivitamins.
had resulted in waist weakness and paralysis of his legs. Despite Laboratory data on admission included: glucose (measured
his paralysis, he maintained a busy work and social schedule. by finger sticks), 166 to 188 mg/dL; hematocrit, 35.6%; albumin,
In his late 50s, he began to complain periodically of “drawing 3.0 g/dL; total calcium, 8.2 mg/dL; inorganic phosphorus, 3.6
a blank”; the symptom probably was due to transient ischemic mg/dL; digoxin, 0.6 ng/mL; cholesterol, 180; triglycerides, 129;
attacks. At age 62, he was examined by several physicians. The HDL, 22; LDL cholesterol, 118 mg/dL; ferritin, 526 ng/mL;
records show that an apical impulse was palpable in the anterior and PTH, 99.9 pg/mL. The EKG was significant for Q-waves
axillary line, and his blood pressure was 180/100 mm Hg, but in leads III and AVR and nonspecific T-wave changes, with
neither an EKG nor a urinalysis was performed. A digitalis no interval changes from the record three months earlier.
preparation was prescribed, but not nitroglycerin. A few months A two-dimensional echocardiogram performed two years
before his death, he was described as “puffy,” was found to ago showed normal global left-ventricular systolic function,
have cardiomegaly and hepatomegaly, and was noted to be left-ventricular hypertrophy, aortic stenosis, and left atrial en-
irritable and somnolent. A few months later, while the patient largement. Angiography revealed moderate, diffuse athero-
was vacationing, he experienced the abrupt onset of headache, sclerotic aorto-iliac disease bilaterally; the left femoral-to-pop-
fainted, and died within two hours. liteal bypass graft was totally occluded. Her left profunda
femoralis was severely diseased, and the left superficial femoralPatient 2 artery was occluded. The patient tolerated the angiographic pro-
A 73-year-old woman with end-stage renal disease had been cedure well, and a below-the-knee amputation was scheduled.
treated with hemodialysis for the past nine years. She had had
non-insulin-dependent diabetes mellitus for 40 years. She was
admitted to the hospital for possible left femoral-popliteal by- DISCUSSION
Dr. Michael S. Goligorsky (Professor of Medicine
and Physiology, State University of New York at StonyThe Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated, AstraZeneca LP; Dialysis Brook, Stony Brook, New York, USA): These two cases
Clinic, Incorporated, and R & D Laboratories. illustrate the entire spectrum of advanced manifestations
of the syndrome under discussion today. The first, whichKey words: endothelin, vascular endothelial growth factor, L-NAME,
hypercholesterolemia, hyperhomocysteinemia, hyperglycemia. you might have recognized as a medical history of U.S.
President Franklin D. Roosevelt [1], depicts the naturalÓ 2000 by the International Society of Nephrology
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history of atherosclerotic disease of coronary and cere- thelium-dependent vasorelaxation has remained the gold
bral arteries, hypertension, transient ischemic attacks, standard in assessing endothelial function and dysfunc-
and a fatal cerebrovascular accident. Although informa- tion [8]. The demonstration of a paradoxical vasocon-
tion on the possible involvement of renal arteries or renal striction in atherosclerotic coronary arteries in response
parenchymal disease is lacking, it is possible that at least to acetylcholine infusion pointed out that defective endo-
one of those could have complicated the patient’s condi- thelial nitric oxide synthase (eNOS) is a crucial parame-
tion and explained the relentless rise in blood pressure. ter characterizing ECD [9]. Indeed, accumulated evidence
The second patient is an unfortunate diabetic woman suggests that many of the disturbances that I have men-
with end-stage renal disease (ESRD) on chronic hemodi- tioned are intimately linked to the expression and func-
alysis with coronary artery disease. She had a coronary tion of this enzyme. In particular, nitric oxide (NO) inhib-
artery bypass graft a few years ago. Peripheral vascular its platelet aggregation and the adhesion of leukocytes
disease and diabetic foot ulcers necessitated amputation to the vascular endothelium [10, 11]. Endothelial regula-
of one foot and a contralateral femoral-to-popliteal by- tion of vascular smooth muscle relaxation, proliferation,
pass graft one year ago; the patient also has recurrent and migration is in part governed by the integrity of the
arteriovenous graft (AVG) problems. This patient is re- L-arginine-eNOS-NO system [12, 13]. In addition, vascular/
ceiving statins, ACE inhibitors, and warfarin; neverthe- endothelial permeability and some synthetic functions
less her vascular problems persist. These patients encom- of endothelial cells have been linked to the activity of
pass the clinical manifestations of a syndrome that only eNOS [7]. Hence, NO production or availability regulates
recently has begun to be defined pathophysiologically at diverse functions of endothelial cells and their interaction
the cellular and molecular level, namely, a syndrome of with circulating formed elements and vascular smooth
endothelial cell dysfunction. Unfortunately, our diagnos- muscle cells.
tic and therapeutic modalities for managing this syn- A solid foundation underlies the thesis that NO pro-
drome remain limited. duction plays a key role in determining endothelial cell
The view prevailing before the 1980s that the vascular functions. Endogenous eNOS is a point of convergence
endothelium represented merely a barrier between the for several stimulatory and inhibitory pathways (Fig. 1).
intravascular and interstitial compartments has been re- The enzyme is activated and NO output increased by
vised over the last two decades. Covering a surface area stimuli such as acetylcholine, ET-1 and ET-3, bradykinin
of approximately 7 m2 and weighing approximately 1 kg, (this mechanism might contribute to the vasorelaxation
the vascular endothelium is in fact a large, albeit a wide- of ACE inhibitors), vascular endothelial growth factor
spread, organ responsible for the regulation of hemody- (VEGF), insulin, IGF-I, endogenous or exogenous opi-
namics, vascular remodeling, and metabolic, synthetic,
ates and cannabinoids, L-arginine, angiotensin II and IV,
inflammatory, and anti- and pro-thrombogenic processes.
estrogens, TGF-b, fluid shear stress, and cyclic strain.Like any other organ, the vascular endothelium is subject
These stimuli are a few among various signals that ele-to dysregulation, dysfunction, insufficiency, and failure.
vate cytosolic calcium concentration and/or increase pro-
tein tyrosine kinase activity [14–23]. The many inhibitoryPathogenesis
influences include stress-induced heme oxygenase-1 withEndothelial cell dysfunction (ECD) is a common pre-
generation of CO, which leads to the inhibition of eNOS;cursor and denominator of various pathologic conditions,
cytokine-mediated (for example, TNF-a) induction ofsuch as stroke, myocardial infarction, hypertension, and
iNOS resulting in massive production of NO and reducedatherosclerosis. The syndrome initially described defec-
oxygen intermediates, which lead to the generation oftive endothelium-dependent vasorelaxation in patients
peroxynitrite; hyperlipidemias (mostly due to the oxidizedat risk for the development of atherosclerosis, even be-
LDL); hyperhomocysteinemia; endogeneous NOS in-fore angiographic or ultrasonographic evidence of the dis-
hibitors (L-NMMA and ADMA); and diabetes mellitusease became detectable [2–6]. The syndrome is currently
and protein modification by advanced glycosylation endinterpreted as encompassing disturbances in several func-
products and high concentrations of glucose per se [24–28].tions: the barrier function of the vascular endothelium;
Clearly, impaired signal transduction along the stimula-its impaired antithrombogenic properties; blunted angio-
tory pathways, as well as the induction of inhibitorygenic capacity; inappropriate regulation of vascular smooth
influences together with scavenging of NO by other mol-muscle tonicity, proliferative capacity, and migratory
ecules, should decrease the availability of NO and pre-properties; perturbed synthetic functions; and failing de-
vent its physiologic functions. It is therefore not surprisingterrence of neutrophils and monocytes from diapedesis.
that eNOS dysfunction has broad consequences affectingSeveral markers of ECD have been proposed, includ-
virtually every aspect of endothelial cell function. Let using elevated circulating levels of von Willebrand factor,
now focus on the functional morphology of eNOS andplasminogen activator inhibitor-1, some adhesion mole-
cules, isoprostane, and thrombomodulin [7]. But endo- on the role of eNOS in perturbed vascular remodeling,
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Fig. 1. Endothelial nitric oxide synthase
(eNOS) is a point of convergence of signaling
pathways responsible for the execution of hemo-
dynamic adaptation in physiologic and patho-
logic conditions. Abbreviations are: VEGF,
vascular endothelial growth factor; IGF-I, in-
sulin-like growth factor-I; iNOS, inducible ni-
tric oxide synthase; CO, carbon monoxide;
LDL, low density lipoprotein; ADMA, asym-
metric dimethylarginine; AGEs, advanced gly-
cosylation end products; TNF-a, tumor necro-
sis factor-a.
angiogenesis, and cell signaling as important manifesta- ratory and others provide convincing evidence that NO
production is a prerequisite for endothelial cell migra-tions of ECD.
tion, wound healing, and angiogenesis [35–37]. We dem-
Functional morphology of eNOS onstrated that endogenous NO production by endothe-
lial cells is a prerequisite for angiogenic effects of VEGF.Early studies demonstrated that eNOS is localized to
Furthermore, studying autocrine effects of endothelins,the Golgi apparatus and cytoplasmic vesicles within en-
we showed that while transmigration of immortalizeddothelial cells. Immunoelectron microscopy revealed
rat renal resistance artery endothelial cells (RMVEC) isthat subcytoplasmic vesicles had various degrees of label-
increased by ET-1, the prior inhibition of NOS withing and suggested that eNOS could be exteriorized and
L-NAME completely abrogates the ET-1-induced cellNO produced extracellularly. A more detailed view came
migration. This locomotive effect appears to be mediatedwith the recognition that eNOS is harbored in caveolae.
via the ETB receptor, is curtailed with antagonists ofCaveolin, the major structural component of caveolae,
forms high-molecular-weight oligomeric structures [29]. this receptor, and is inhibited with the use of antisense
Endothelial NOS is targeted to caveolae and interacts oligonucleotides to eNOS. Hence, we concluded that
directly with caveolin-1, as shown by their co-immuno- ET-1 or ET-3 stimulates endothelial cell migration and
precipitation. This interaction occurs via the caveolin-1 wound healing via the ETB receptor, and that the coupling
scaffolding domain and inhibits eNOS’ enzymatic activ- of this receptor to eNOS is critical not only for NO produc-
ity [30, 31]. The inhibitory conformation of eNOS is re- tion but for endothelial cell migration as well [20, 38]. A
versed by the addition of excess Ca11/calmodulin [32, 33]. cell-permeant analogue of cyclic GMP, 8-bromo-cyclic
Agonists stimulating eNOS, such as bradykinin, promote GMP, restored ET-1-induced locomotion of endothelial
subplasmalemmal translocation of the enzyme [34]. cells pretreated with L-NAME. This finding suggests that
Thus, the current view of eNOS shuttling between the the effect of NO on cell migration is mediated via the
caveolar coat and the cytoplasm suggests some intricate cyclic GMP signaling pathway [20, 39].
mechanisms of its regulation. To determine the pertinence of the in vitro findings
to the in vivo effects of VEGF and ET, we utilized two
Vascular remodeling experimental settings. First, E. Noiri in my laboratory
has demonstrated that VEGF-impregnated filter disksFormation of new blood vessels, driven by the func-
tional demand for oxygen and increased blood supply, implanted on the avascular pole of the chick chorioallan-
toic membrane (CAM) stimulated angiogenesis, whereasis initiated by the budding of endothelial cells off the
microcirculatory bed. Tissue hypoxia is the major physio- this process was inhibited in the presence of L-NAME
(Fig. 2). Second, we developed a rat model to study thelogic stimulus for angiogenesis, and several autocrine
angiogenic mediators have been recognized, including angiogenic potential of test compounds [39]. Kidneys
were exposed surgically and injected with 0.2 mL ofVEGF and endothelin-1 (ET-1). Studies from our labo-
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Fig. 2. Vascular endothelial growth factor
(VEGF)-driven angiogenesis in chorioallan-
toic membranes (CAM) requires a functional
endothelial nitric oxide synthase (eNOS). Discs
impregnated with a vehicle (A), VEGF (B),
L-NAME (C), or VEGF 1 L-NAME (D) were
placed on the CAM’s surface at the avascular
pole, incubated for 72 hours, excised, fixed,
and imaged to visualize the degree of neovas-
cularization. While VEGF alone doubled the
length of vessels on discs, L-NAME alone or
in combination with VEGF significantly abro-
gated the angiogenic response. Bar in (D) 5
2 mm.
collagen I premixed with ET-3 with or without L-NAME. tance? Fledgling evidence suggests that microvascular
remodeling continuously adjusts blood supply to normalAnimals were allowed to recover for seven days, after
which time they were sacrificed. After flushing the kid- tissues, but that remodeling can be greatly enhanced
when conditions become abnormal. The failure to in-neys with 0.9% NaCl, we injected a vascular-casting ma-
terial, Mercox resin, into the renal arteries. Vascular crease vascular remodeling may well be the precursor
of fibrotic transformation. For instance, various renalcasts were prepared by maceration in 20% NaOH until
the parenchyma was completely dissolved. Injection of diseases leading to interstitial fibrosis are associated with
a decreased number of blood vessels seen on biopsy [44];collagen alone resulted in an avascular “cavity” at the
cortical site of injection. When injected material con- this association suggests that angiogenesis at these sites
is inappropriate. Similarly, uremic patients show a myo-tained ET-3, cavities were almost completely occupied
with the newly formed vessels (Fig. 3). In contrast, this cyte/capillary mismatch that results in increased distances
for oxygen diffusion required to reach cardiomyocytesphenomenon was dramatically attenuated in kidneys in-
jected with ET-3 and L-NAME. These in vivo observa- [45]; this abnormality is believed to contribute to the
increased risk of myocardial ischemia and developmenttions confirm the in vitro findings and re-emphasize the
importance of functional eNOS in mediating the angio- of cardiac interstitial fibrosis. Therefore, understanding
the mode of NO’s action in supporting angiogenesis hasgenic effects of VEGF and ET. Two independent groups
have recently provided strong in vivo evidence of eNOS profound clinical implications.
We examined the mode of NO action on endothelialinvolvement in vascular remodeling and angiogenesis
using eNOS knockout mice [40, 41]. cell migration in the following series of experiments. First,
using a sensitive cell-impedance device, we demon-These observations led us to propose that endothelial
cell migration and angiogenesis require simultaneous ac- strated that NO stimulates micromotion in cultured en-
dothelial cells; we termed the process “podokinesis” [36]tion of at least two signals—functional eNOS generating
NO, and guidance cues, for example, ET-1 or VEGF—to to indicate accelerated turnover of focal adhesions. Sec-
ond, when we cultured endothelial cells on a flexibleimpart on the cells the necessary direction of movement
[36, 42, 43]. silicone rubber substratum and recorded the wrinkling
phenomenon using time-lapse videomicroscopy, we wereDo these experimental data have any clinical impor-
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Fig. 3. Scanning electron micrographs of vascular castings of kidneys injected with collagen-1 plaque containing endothelin (ET)-3 (A) or ET-3
in combination with L-NAME (B). Note that ET-3 alone resulted in almost complete neovascularization of the plaque, whereas angiogenesis was
blunted by the addition of NOS inhibitor. Magnification 375,000. (Reprinted with permission from Acta Physiol Scand [39]).
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able to document that addition of sodium nitroprusside
resulted in the resolution of tractional forces on the sub-
stratum, whereas NO inhibition increased them [36, 37].
In a search for the target(s) for this action of NO, we
investigated components of the molecular chain respon-
sible for the development of tractional forces, that is,
extracellular matrix molecules, integrins, focal adhesion
kinase, and adaptor proteins [46–49], as well as the actin
cytoskeleton. These studies demonstrated that NO donors
primarily affect the state of tyrosine phosphorylation
of focal adhesion kinase (FAK) and paxillin, probably
because of the biphasic inhibition of tyrosine phospha-
tases and tyrosine kinases. In addition to this, an NO-
induced decrease in protein kinase Cd activity also has
been incriminated in the acquisition of a migratory phe-
notype by endothelial cells [50]. The resultant physio-
logic effect consists of increased turnover of focal adhe-
sions, partial relaxation of tractional forces applied on
the substratum, and acquisition of the state of cell-matrix
interactions, which optimizes podokinesis (scalar motion)
to the physiologic requirements for angiogenesis (if gra-
dients of guidance cues—ET or VEGF—are present).
Considering the facts that eNOS is localized to caveolae
on the plasma membrane, and that b1 integrins also are
present in these organelles in endothelial cells, one can
envisage a possible link between caveolae and eNOS on
the one hand, and cell adhesion, locomotion, and vascu-
lar remodeling on the other.
Several years ago we observed a phenomenon of NO-
induced termination of ET signaling [51]. With the ad-
vent of knowledge about the spatial organization of ele-
Fig. 4. Hypothesis of NO-induced caveolin-1 transition from the oligo-ments of signaling cascades initiated via some serpentine meric to the monomeric form. Once the scaffolding has been disrupted,
receptors localized to caveolae [52, 53], it has become pos- the elements of signaling cascades harbored in caveolae become dis-
tanced and signal transduction uncoupled. (A) intact scaffolding struc-sible to obtain additional mechanistic details on NO termi-
ture; (B) scaffolding disintegrated by NO.nation of signal transduction. Specifically, we explored the
possibility of a feedback action of NO on caveolin [54].
Application of an NO donor, sodium nitroprusside (SNP),
induced a time- and concentration-dependent increase cations. In particular, stimulation of NO production
should result in the increased turnover of focal adhesionsin the monomeric form of caveolin in cultured human
umbilical vein endothelial cells (HUVEC). This effect and acquisition of the migratory phenotype by endothe-
lial cells, as I mentioned. In addition, one would expectwas mimicked by cGMP. To visualize caveolin in situ,
HUVEC were transfected with a pEGFP-C vector con- that in diseases accompanied by the reduced generation
of NO in response to endothelium-dependent vasoactivetaining the caveolin-1 cassette encoding a GFP-caveolin
fusion protein. Exposure of HUVEC to SNP rapidly dis- substances, such as ET or angiotensin, cell motility would
be diminished, while the duration of signaling would bepersed the GFP-caveolin from pre-existing clusters; this
dispersal suggested the NO-induced change in the oligo- prolonged because of the failed termination of signal
transduction. In fact, this deficiency in NO formationmeric state and cellular localization of caveolin. Bradyki-
nin mimicked the effect of SNP in an eNOS-dependent might be one of the contributors to hypertension. On the
other hand, excessive generation of NO through iNOSmanner. These data demonstrate that NO terminates
ligand-receptor intracellular signaling by dissociating the should result in the protracted spatial dissociation of
caveolae-enriched elements of signaling cascades. In-oligomeric caveolin and probably distancing the trans-
ducing elements in signaling cascades residing in caveo- deed, a similar phenomenon of reduced responsiveness
to vasoactive stimuli is observed in septicemia.lae (Fig. 4).
This mode of topologic regulation of signaling cascade Hence, NO production provides the cell with a tuning
fork mechanism to adjust the tightness of cell-matrixmight have important physiologic and pathologic impli-
Nephrology Forum: Endothelial cell dysfunction and NO synthase1366
Fig. 5. Schematic view of the relationship
among NO generation, endothelial cell adhe-
sion, and migration rate. (Shaded area denotes
NO concentration.)
adhesions to the physiologically required rate of cell fulfilled for vectorial cell movement along the gradient
of angiogenic substances to occur [55–57]. This workingmigration (Fig. 5). For instance, in the resting state, endo-
thelial cell adhesion is that of a spread, tightly attached hypothesis might explain some pathologic situations ac-
companied by the inappropriate generation of NO.cell which, upon activation and NO generation, develops
an intermediate strength of adhesion and is “prepared” Generation of ET-1 is augmented in hypercholesterol-
emic pigs and in humans with atherosclerotic lesionsfor vectorial locomotion. When such a cell is presented
with the guidance cues (ET or VEGF), its chemical gradi- [58]. The reason for the insufficient angiogenesis towards
ent results in a gradient of tyrosine phosphorylation/de- ischemic sites could be explained by the fact that NO
phosphorylation of FAK and paxillin, thus determining production by the endothelium is suppressed under these
the leading and trailing edges. Indeed, when cells are conditions [59–61]. Similarly, endothelial wound healing
migrating toward a VEGF source, application of a tyro- after balloon angioplasty is retarded, neointimal forma-
sine kinase inhibitor, genistein, significantly inhibits vec- tion by proliferating smooth muscle cells is increased,
torial movement [37]. These data further emphasize the and the endothelin receptor antagonist SB 209670 pro-
relation between scalar and vectorial motion in endothe- tects angioplastic vessels against neointimal formation
lial cells (Fig. 5). When the level of NO production be- [62]. Interpretation of these observations again rests on
comes supraphysiologic, cells tend to detach from the the presented finding of the permissive role of NO in
matrix, while subphysiologic levels of NO generation endothelial cell migration and wound healing. Based on
lead to the excessively tight cell-matrix adhesion; in both the contribution of endothelial cell migration to angio-
instances endothelial cells are unable to respond appro- genesis, these data likely implicate insufficient NO pro-
priately to angiogenic stimuli. With this in mind, the duction in pathologic states (such as atherosclerosis,
advanced understanding of the dual signaling input for heart failure, and hypertension) in the inappropriate re-
endothelial cell migration consists of (1) NO-dependent sponse to angiogenic stimuli. Furthermore, this aspect
turnover of focal adhesions, which represents a scalar of NO’s action in endothelial cells might explain in part
motion (podokinesis), and (2) guidance cues, for exam- the antiatherogenic effect of NO [63, 64].
ple, VEGF or ET, which determine the direction of
Vascular permeabilitymovement by assigning, through gradients in tyrosine
phosphorylation, the leading and trailing edges of the At least three different mechanisms regulating micro-
vascular permeability have been described. The first iscell. The requirement for podokinetic motion has to be
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non-selective permeability due to the gap formation be-
tween endothelial cells [65], which might be responsible
for the leakage of intravascular macromolecular and cel-
lular components to the interstitium under inflammatory
conditions. Second, fenestrae are formed in endothelial
cells subjected to the paracrine effect of the elevated
local VEGF production [66]. Increased permeability of
the vasculature to macromolecules might ensue in re-
sponse to the formation of fenestrae. Third, in some
situations, VEGF results in the formation of vesiculo-
vacuolar organelles (VVOs), which represent invaginated
caveolae fusing in a vectorial fashion to create transcellu-
lar channels [67].
Using caveolin-1-green fluorescent protein (GFP) vec-
tor, we were able to monitor in vivo the dynamics of
caveolin in endothelial cells stimulated with VEGF. Con-
focal microscopy demonstrated formation of transcellu-
lar channels decorated by GFP; these channels were
permeable to molecules like horseradish peroxidase ap-
proximately 30 minutes after application of VEGF. In
endothelial cells, VEGF stimulates eNOS, so the role of
NO in endothelial permeability has been investigated.
In vivo, L-NAME application rapidly increased albumin
extravasation, adherence and immigration of leukocytes,
and generation of reduced oxygen intermediates in post-
capillary venules [68]. In addition, activation of eNOS
and the generation of NO might reduce endothelial per-
meability stimulated by agents like thrombin [69]. How-
ever, the concurrent increase in the production of reduced
oxygen intermediates, for instance, in inflammatory states,
could reverse this effect of NO and result in peroxyni-
trite-induced elevation of endothelial permeability. Our
scanning electron microscopy data on the integrity of
Fig. 6. Scanning electron micrographs of endothelial cell monolayersendothelial monolayers subjected to sodium nitroprus- subjected to (A) vehicle or (B) 100 mmol/L peroxynitrite for 30 minutes.
side or peroxynitrite demonstrate a remarkable effect of Note large gaps in the monolayer (B), presumably the sites of previously
nested desquamated cells, and intercellular gaps.the latter on gap formation (Fig. 6). Clearly, different
mechanisms and routes of endothelial permeability dic-
tate the need for us to re-examine these issues in much
greater detail. occurs in endotoxemia, when the generation of peroxyni-
trite leads to ECD [71]. Tyrosine nitration, an indicator
Mediators of peroxynitrite production, has been demonstrated in
Fledgling evidence implicates several pathophysio- atherosclerotic plaques, smooth muscle, and “foam cells”
logic stimuli that are known or presumed to mediate in lungs of patients with respiratory distress and in ische-
ECD in the inhibition of eNOS or in scavenging of NO. mic, endotoxic, or nephritic kidneys [70, 72, 73]. I should
Reduced oxygen intermediates and generation of peroxy- mention that other metabolites of nitric oxide also are
nitrite. When generation of superoxide anions accompa- incriminated in the formation of 3-nitrotyrosine. Eiserich
nies NO release, the high rate of reaction between these et al have demonstrated that this effect is due to the
two molecules results in a predominant formation of generation of nitryl chloride and nitrogen dioxide, prod-
peroxynitrite. This highly toxic intermediate of oxidative ucts of the reaction between nitrite, hypochlorous acid,
and nitrosative stress leads to formation of iron-nitrosyl and myeloperoxidase, and emphasized the role of neu-
complexes, nitrosothiols, oxidized sulfhydryls, nitrotyro- trophils and monocytes in nitration reactions (Fig. 7)
sine residues (used as indicators of peroxynitrite forma- [74]. Nitrotyrosine’s modification of low density lipopro-
tion), and hydroxyl radical generation, which produces tein (LDL) has been incriminated in its atherogenic ac-
DNA strand breaks [70]. These reactions underscore the tivity. Indeed, incubation of monocytes with low density
lipoprotein (if LDL was modified in the presence ofcytotoxic properties of peroxynitrite. A typical scenario
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Fig. 7. Summary of biochemical pathways
leading to the nitrosative stress in endothelial
cells and formation of nitrotyrosine-modified
proteins. The central portion of this cartoon
illustrates some known inhibitors of specific
pathways.
myeloperoxidase, hydrogen peroxide, and nitrite) leads scription and expression [81]. An additional mechanism
of LDL-induced impairment of NO generation has beento a rapid formation of “foam cells” [75]. Oxidized LDL
stimulates monocyte adhesion to glomerular endothelial linked to the fact that LDL results in the predominant
generation of superoxide radicals by eNOS itself [82].cells [76], although the effects of nitrotyrosine’s modifi-
cation of LDL remain to be determined. Another physio- In turn, NO deficiency is responsible for the induction
of the macrophage-colony-stimulating factor gene andlogically important consequence of peroxynitrite produc-
tion is attributed to the selective nitration of prostacyclin an influx of macrophages [83]. Treatment with tetrahy-
drobiopterin (BH4) reversed the defect in NO generationsynthase, which results in the defective vasorelaxation
seen in atherosclerotic bovine coronary arteries [77]. Due and reduced superoxide production in young patients
with familial hypercholesterolemia without detectableto the accumulating nitrosative modification of slowly
metabolizable proteins, like matrix proteins and cyto- macrovascular disease [84]. In addition, the atherogenic
effect of hypercholesterolemia might be due to the in-skeletal elements, the cytoarchitectonics are significantly
altered by peroxynitrite. One of the consequences is cell creased generation of peroxynitrite (secondary to the im-
paired glutathione detoxification mechanism) and proteindetachment from the matrix [43], as revealed by scanning
electron microscopy of endothelial cell monolayers pre- modification by nitrotyrosylation, which has been docu-
mented in atherosclerotic lesions [70]. One of the promi-treated with peroxynitrite (Fig. 6). By impairing the in-
tegrity of the vascular endothelium, peroxynitrite expo- nent receptors for oxidized LDL on endothelial cells,
LOX-1, is up-regulated by angiotensin II or shear stress,ses the smooth muscle layer to the circulating signals
and thus might reverse its responses to vasoactive com- so activation of the renin-angiotensin system in many
forms of hypertension, as well as in hemodialysis pa-pounds.
Hypercholesterolemia and elevated LDL. As I men- tients, might be responsible for the accelerated athero-
genesis [85]. In fact, recent findings from Casellas’ labo-tioned, hypercholesterolemia is associated with impaired
endothelium-dependent vasodilation even before any mor- ratory demonstrate that in the absence of hyperlipidemia,
inhibition of eNOS alone is sufficient to induce the depo-phologic changes in blood vessels occur [2, 3]. It has been
known for 10 years that oxidized LDL and its constituent sition of Sudan-black-positive lipid droplets in arcuate
and interlobular renal arteries, but not in afferent arteri-lysophosphatidyl-choline impair NO-induced relaxation
[78]. This phenomenon might be due to the recently de- oles, and result in increased vascular wall thickness [86].
This is an important demonstration of the role of endo-scribed effect of hypercholesterolemic serum on the an-
chorage of caveolin-eNOS, which inhibits NO produc- thelial NO deficiency in leading to atherosclerotic dam-
age to medium-sized renal arteries.tion [79]. In addition, hyperlipidemia could affect eNOS
through intermediates of nitrosative and oxidative stress. Hyperhomocysteinemia. Hyperhomocysteinemia is an
independent and graded cardiovascular risk factor equalNitrosylation of LDL cholesterol by peroxynitrite oc-
curs, especially in atherosclerotic plaques, and contrib- in strength to that of hyperlipidemia. Hyperhomocys-
teinemia is prevalent in patients with chronic renal failure,utes to lipid peroxidation [80]. Furthermore, oxidized
LDL has been implicated in the inhibition of eNOS tran- and mortality rates in patients with homocysteine levels
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above 20 mmol/L are about seven times greater than duce many of the vascular complications of diabetes [99].
Recent data have demonstrated that AGEs consumethose in patients with plasma levels below 9 mmol/L. In
a recent study of patients with end-stage renal disease endothelium-derived NO, thus compromising vasodila-
tory responses and diminishing NO’s antiproliferativeundergoing hemodialysis, hyperhomocysteinemia was a
universal finding and was independently associated with action [100, 101]. Although substantial literature exists
on the stimulation of this family of enzymes in diabetica history of cardiovascular events [87]. Using an ampero-
metric electrochemical NO detection with a porphyrinic animals and humans, the biologic effects of NO appear
to be defective [102, 103]. These findings of NO quench-microelectrode, we examined responses of microvascular
endothelial cells incubated for different periods of time ing by AGEs might explain the observed deficiency in
angiogenic responses (which require basal NO produc-with increasing concentrations of homocysteine to stimu-
lation with l-arginine or with bradykinin [88]. Twenty- tion) at sites of interstitial fibrosis. In addition, this func-
tional NO deficiency might complement other factorsfour hour preincubation with homocysteine (10, 20, and
50 mmol/L) resulted in a dose-dependent decline in respon- in stimulating the proliferation of fibroblasts and the
accumulation of extracellular matrix, both of which aresiveness of endothelial cells to bradykinin and l-arginine.
In conclusion, the direct measurement of NO release important contributors to the progression of human dia-
betic nephropathy [104].from cultured microvascular endothelial cells demon-
strated that 20 mmol/L and higher concentrations of Asymmetric dimethylarginine. Several synthetic l-argi-
nine analogues, broadly used in pharmacologic studieshomocysteine significantly suppress eNOS activity. This
demonstration of an inhibitory effect of homocysteine to inhibit eNOS, have been recognized as naturally oc-
curring compounds [105]. These methylarginines areon the eNOS might explain the development of cardio-
vascular complications, especially in dialysis patients found not only in some proteins, but are present in the
cytosol (5 to 10 mmol/L), circulate in the plasma (0.4with universally elevated levels of homocysteine.
Hyperglycemia. The development of microvascular as mmol/L), and are excreted in the urine (5 to 20 mmol/L
in human urine). Accumulation of asymmetric dimethyl-well as macrovascular complications in patients with dia-
betes has been linked to the quality of glycemic control arginine (ADMA) has been documented in patients with
renal failure. Considering the fact that the half-maximal[89–91]. The chronic vasoconstrictive effect of hypergly-
cemia has been attributed to advanced glycosylation end effective concentration for ADMA on eNOS in vivo is
approximately 18 mmol/L, it is possible that this l-arginineproducts quenching NO in the subendothelial compart-
ment, where they accumulate in diabetic animals and in- analogue participates in the development of functional
eNOS deficiency in these patients. Increased circulatingterfere with NO’s action on vascular smooth muscle cells
[92]. However, evidence indicates an additional mode of levels of ADMA also have been described in hypercho-
lesterolemic rabbits and humans as one of the causes forglucose action, based on the finding that impaired endo-
thelium-dependent vasodilation is observed as quickly as suppressed eNOS activity [106].
15 minutes after induction of topical hyperglycemia [93].
ConclusionsTo address the possibility of glucose directly affecting
the function of eNOS, we monitored NO generation by Let’s return to the case presentations. It is likely that
today, with the available antihypertensive agents, ACEthe recombinant eNOS in vitro [94]. Application of 25
mmol/L glucose to the incubation medium consistently inhibitors, and statins, we could have prolonged FDR’s
life, but the case history of the second patient still posesreduced detectable NO. The addition of glucose to NO
solutions resulted in a dose-dependent decrease in NO insurmountable therapeutic problems related to general-
ized endothelial cell dysfunction. Several therapeuticconcentration. Mass spectrometry provided evidence of
a direct chemical reaction between glucose and NO. strategies are emerging (Fig. 8). Initial attempts have been
made to inhibit or even reverse ECD with l-arginineTaken together, our findings suggest that oxidant stress
in combination with hyperglycemia inactivates NO and supplementation, ascorbic acid, folic acid, and other anti-
oxidant compounds. The proponents of l-arginine sup-thereby contributes to the ECD of diabetic vasculopathy.
Advanced glycosylation end products. Advanced gly- plementation described improvement of endothelium-
dependent vasodilation in cholesterol-fed rabbits and incosylation end products (AGEs) are considered among
the leading causes of diabetic complications in humans, patients with hypercholesterolemia [106–109]. Similarly,
l-arginine appears to ameliorate reperfusion injury afterespecially in the development of atherosclerotic vascular
disease [95–97]. Advanced glycosylation end products myocardial ischemia, inhibit intimal hyperplasia after
balloon-catheterization-induced endothelial injury, andare linked to changes in physicochemical properties of
matrix proteins, such as collagen-to-collagen cross-link- attenuate endothelial adhesiveness in hypercholesterol-
emia [110–112]. On the other hand, a randomized, double-ing and tissue rigidity, which lead to decreased solubility
and susceptibility of proteins to enzymatic digestion [98]. blind, placebo-controlled study of l-arginine supplemen-
tation in patients with moderate chronic renal failure didIn fact, AGE infusion to non-diabetic animals can repro-
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Fig. 8. Therapeutic targets for prevention or
reversal of endothelial cell dysfunction and
some putative pharmacologic modalities acting
on these targets. Abbreviations are: VEGF,
vascular endothelial growth factor; ADMA,
asymmetric dimethylarginine; RAGE, recep-
tor for advanced glycosylated end products.
not improve renal function [113]. In hypercholesterol- and BH2, as cofactors triggering the alternative synthesis
of NO or superoxide radical by eNOS, explains the bene-emic rabbits, supplementation with l-arginine causes re-
gression of pre-existing lesions. This effect is attributed ficial effects of folates on endothelium-dependent NO
production under various circumstances. Another anti-to the induction of apoptosis of macrophages in athero-
mas [114]. oxidant, probucol, preserves endothelial function in hy-
percholesterolemic rabbits, thus giving further credibilityEvidence suggests that in vivo transfer of the eNOS
gene or treatment with S-nitroso-albumin can inhibit neo- to the strategy of limiting oxidant stress and its conse-
quences [120].intimal vascular lesions [115, 116]. Both therapies prob-
ably are relevant to future attempts to retard stenotic The ability of 3-hydroxy-3-methylglutaryl-CoA reduc-
tase inhibitors (statins) to ameliorate endothelial dys-lesions in arteriovenous fistulas. In addition, synthesis
of NO-aspirin reportedly combines the benefits of both function exceeds its lipid-lowering ability [121]. Lamas’
group has recently demonstrated that statins prevent theingredients and improves inhibition of inflammatory and
thrombotic pathways [117]. The role of these strategies in suppression of eNOS mRNA by oxidized LDL in endo-
thelial cells [122]. The authors also showed that statinsameliorating atherosclerotic lesions remains unknown.
A different approach for local gene transfer has been inhibit pre-pro-endothelin-1 mRNA expression and en-
dothelin synthesis in cultured endothelial cells. Theseadvocated by Laitinen et al, who applied a silicone collar
to the adventitial surface of carotid arteries and used it effects of statins underlie their proposed efficacy in im-
proving ECD.as a reservoir for plasmid/liposome-mediated VEGF gene
transfer [118]. Overexpression of VEGF prevented intimal Treatment of hypercholesterolemic rabbits with se-
vere ECD using 17b-estradiol improves endothelium-thickening, and this effect was NO-dependent. Whether
such an approach can be utilized in the prevention or dependent vasorelaxation while reducing the size of ath-
eromas without altering serum cholesterol level in thesetreatment of arteriovenous fistulas in hemodialysis pa-
tients remains an open question. animals [123]. Similarly, estrogens reduced atheroscle-
rotic lesions in apolipoprotein E-deficient mice [124].Supplementation with folic acid (5 to 10 mg/day) or its
active circulating metabolite, 5-methyltetrahydrofolate, Although these effects were in part NO-dependent, the
precise mechanism of estrogen anti-atherogenic actionrestores impaired endothelium-dependent vasodilation
in patients with hyperhomocysteinemia or hypercholes- is not known.
Hence, the data linking eNOS function and NO gener-terolemia [119]. This effect appears to be a more complex
one than reduction of the level of homocysteine; rather, ation to vascular remodeling and signaling, hyperlipid-
emias, AGEs, and hyperglycemia should be viewed withinit can be metabolically related to the improved genera-
tion of BH4 from BH2 and improved antioxidant defense. the broader framework of the syndrome of endothelial
cell dysfunction. It is possible that phenomena relatedIn such a case, restoration of the balance between BH4
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to inadequate neovascularization of ischemic foci and thelial NO system in endothelial cell migration, vascular
remodeling, and angiogenesis?defective mechanisms of signal transduction or termina-
Dr. Goligorsky: Genetically engineered animals havetion, as well as increased adhesion of leukocytes, loss of
been used to address the question of the role of NO inantithrombogenic properties, proliferation of vascular
angiogenesis [40, 41]. The short answer to your questionsmooth muscle cells, and changed patterns of matrix
is that embryonic angiogenesis does not seem to be per-deposition, each just slightly perturbed, collectively can
turbed by NO deficiency. However, the processes oftrigger early, preclinical forms of ECD. We need to learn
wound healing or collateral circulation are significantlymore about noninvasive ways of assessing the functional
hampered when eNOS function is defective, either bystate of eNOS and the availability of NO in our patients.
antisense oligonucleotide treatment or the deletion ofTherefore, future directions of research in this area
the eNOS gene.should define early preclinical markers of ECD and be
Dr. Andrew J. King (Division of Nephrology, Newbased on a better understanding of vascular remodeling
England Medical Center, Boston): As nephrologists, weand endothelial cell activation and intracellular signaling.
see many patients who have co-morbid conditions thatWith the accumulating evidence that disturbances of NO
affect endothelial cell function, such as hypertension andproduction or availability represent early determinants
hypercholesterolemia. Frequently, our patients have ad-of ECD, we should intensify the studies on therapeutic
vanced disease both in the kidneys and in the vasculature.correction of eNOS or increased availability of NO.
You alluded to the possibility of “assessing” endothelial
cell function prior to the onset of advanced disease. Do
QUESTIONS AND ANSWERS you think there is any utility in doing some sort of func-
tional test to assess endothelial cell integrity, such asDr. Nicolaos E. Madias (Executive Academic Dean,
response to endothelium-dependent vasodilators or mea-Tufts University School of Medicine, Boston, Massachu-
surement of endothelial cell markers?setts): You touched upon atherosclerosis and mentioned
Dr. Goligorsky: I am absolutely certain that in thethat it is characterized by endothelial dysfunction. Further,
very near future we shall be able to examine eNOSa number of stresses that induce endothelial dysfunction,
function of our patients. This ability will enable us tofor example, hypertension, diabetes, hyperlipidemia, and
diagnose endothelial cell dysfunction long before anysmoking, all are risk factors for atherosclerosis. On the
morphologic stigmata of vascular disease become detect-other hand, human atherosclerotic lesions, but not nor-
able by the Doppler or radiologic techniques. I referredmal vessels, have widespread expression of iNOS in en-
in my talk to the invasive tests requiring cardiac catheter-dothelial cells as well as in vascular smooth muscle cells
ization—these tests were instrumental in defining endo-and macrophages. In this regard, atherosclerosis is now
thelial dysfunction as the syndrome characterized by in-recognized as a chronic inflammatory process. Can you
appropriate endothelium-dependent relaxation and NOcomment on the potential role of iNOS expression against
production [8]. Our task is to develop the noninvasive
the background of endothelial dysfunction in the patho-
tools that will enable us to discern the patterns of endo-
genesis of atherosclerosis? thelial cell dysfunction and thus guide our therapies.
Dr. Goligorsky: That is a profound and interesting Dr. John T. Harrington (Dean, Tufts University
question with no unequivocal answer yet. Cytokine- School of Medicine): Do glomerular endothelial cells
induced or hypoxia-induced iNOS has been detected in function substantially differently than do non-glomerular
atherosclerotic lesions. Potential functions of iNOS in endothelial cells? Second, is there a way to enhance the
this setting are many. On the one hand, iNOS can be delivery of eNOS into the specific cells that you would
involved in the formation of oxidized LDL, a key pro- like to stimulate?
atherogenic mediator, in the subendothelial compart- Dr. Goligorsky: The answer to your first question
ment, thus initiating the formation of a fatty streak [80]. is yes: glomerular endothelial cells are physiologically
It also can suppress the function of eNOS by NO-induced fenestrated, and this feature distinguishes them from the
inhibition of this enzyme. On the other hand, iNOS can majority of vascular beds. This property is believed to
halt the proliferation of smooth muscle cells and inhibit derive from the podocytes synthesizing vascular endo-
neointimal formation. Furthermore, NO derived from thelial growth factor and its ability to stimulate fenestra-
iNOS might be involved in the process of apoptotic “foam tion. Glomerular endothelial cells also express eNOS in
cell” death and recruitment of macrophages to the vascu- abundance. It has been suggested that endothelial cells
lar wall to phagocytose these cells. To summarize, in this from different vascular beds are characterized by certain
particular situation iNOS function depends on the bio- organ-specific epitopes. However, these remain to be
logic context and the staging of the atherogenic process. discovered.
Dr. Madias: Is there any information about using Regarding your second question, specific delivery of
eNOS to endothelial cells at a certain location remainsknockout animals for eNOS to test the role of the endo-
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a challenge. While there are strategies to deliver eNOS Dr. Goligorsky: The possibility of ACE inhibitors
to the sites of angioplasty [115] or to anastomotic sites alleviating the severity of ECD does exist, as your ques-
[118], these techniques are invasive. One would hope to tion implies. Stimulation of endothelial cells and eNOS
achieve the same goal by injecting cDNA systemically. might be a result of inhibited degradation of bradykinin,
This, however, will require some targeting motif, which as well as an anti-oxidant effect of some ACE inhibitors.
is currently unknown. The answer to this problem proba- Dr. Vikas P. Sukhatme (Chief, Division of Nephrol-
bly is hidden in the answer to your first question, namely, ogy, Beth Israel Deaconess Medical Center, Boston): Re-
defining the site-specific epitopes in glomerular endothe- garding tumor angiogenesis, your discussion would sug-
lial cells. gest that inhibition of eNOS or NO activity might be an
Dr. Harrington: My understanding of most of the appropriate target; such inhibition would lead, however,
comparable transfection studies is that of the 100% of to unfortunate consequences for all the reasons you just
what is injected, transfected, transferred, or delivered, mentioned. Do you agree that systemic blockade might
only a small percentage actually gets where the investiga- be problematic? Also, are there ways of locally blocking
tor would like it to go, probably 1% or so. How do you eNOS?
increase that 1% to 10%? Dr. Goligorsky: This is again a problem of targeting.
Dr. Goligorsky: You have touched on one of the Indeed, as you mention, there is solid evidence connect-
most contentious questions of today’s gene therapy: How ing NO production with tumor angiogenesis; when NO
can we improve the efficiency of transfection? I fear that production is inhibited, tumor growth is stagnated. Thus,
there is no ready answer to this question. On the other one wonders how to curtail angiogenesis to the sites of
hand, as it pertains to eNOS, I believe that the problem malignant cell growth without interfering with NO func-
of endothelial cell dysfunction lies not so much in the tion in protecting the vasculature from atherogenic fac-
low level of expression of the enzyme, but in the reduced tors. Tumor endothelial cells express certain epitopes, like
activity of eNOS or, even more important, in the func- the expression of aVb3 integrins and perhaps others, which
tional switch of the enzyme from a NO-generating one could potentially serve as conduits for anti-angiogenic
to a superoxide-producing one. It will be our next chal- therapies, not compromising the rest of the endothelium.
lenge to learn how to transform eNOS to the NO-gener- I agree with you that systemic approaches to the problem
ating mode of activity. of tumor angiogenesis may be premature, unless the
Dr. King: Glomerular endothelial cells are continu- target is expressed exclusively in tumor vessels.
ously exposed to high shear stress. In animals with 5/6 Dr. Madias: What is our understanding of the role of
nephrectomy, progression is accelerated and proteinuria nitric oxide in the special susceptibility of certain vascu-
is increased by agents that interfere with nitric oxide
lar beds to thrombotic microangiopathies?
production. Nitroglycerin has been used in clinical prac-
Dr. Goligorsky: One of the early lesions in patientstice for a long time, yet it doesn’t appear to protect
with hemolytic-uremic syndrome (HUS) occurs in severalagainst atherogenesis. Although nitroglycerin clearly has
vascular beds, especially in the kidney, and is character-anti-anginal properties, I’m unaware of evidence that it
ized by detachment of endothelial cells from the base-prevents heart attacks or other acute vascular events.
ment membrane, similar to that occurring in vitro, asWhy do you think that is?
shown in Figure 6. The role of iNOS and peroxynitriteDr. Goligorsky: Your interesting question is tightly
generation in early HUS has been suggested by studiesconnected to the problem of eNOS’ mode of function.
from Dr. Remuzzi’s laboratory. Loss of the integrity ofData suggest that NO is anti-atherogenic [83, 114].
the endothelial barrier is most probably a prerequisite forWhether nitroglycerin can substitute for the proper eNOS
development of thrombotic microangiopathy. Denudedfunction is questionable. Development of tolerance to
vascular basement membrane initiates platelet aggrega-nitroglycerin is a real problem, and one that has been
tion and thrombotic sequelae characteristically observedlinked to the ongoing induction of oxidant stress in ath-
in this syndrome.erosclerotic vessels. This process has several conse-
Dr. Tauqeer Karim (Nephrology Fellow, Division ofquences: it diverts NO from its targets by generating
Nephrology, New England Medical Center): I would likeperoxynitrite, suppresses the activity of eNOS, and exerts
to hear your thoughts on the beneficial role of aminoguani-cytotoxic effects. Therefore, in my opinion, one should
dine in the prevention of diabetic nephropathy. Evidenceuse a combination of therapeutic modalities, such as anti-
in animal studies suggests that aminoguanidine preventsoxidants, L-arginine, statins, methyltetrahydrofolates,
the development of nephropathy by inhibiting the forma-tight glycemic control, and physical exercise to achieve
tion of advanced glycosylation end products. However,optimal anti-atherogenic results.
studies evaluating its effects in humans have been tempo-Dr. Madias: You mentioned cholesterol-dependent
rarily suspended because of drug side effects. Do youand -independent effects of statins in repairing endothe-
lial dysfunction. What do we know about ACE inhibitors? believe that the new protein glycosylation inhibitors cur-
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tions for therapy of cardiovascular diseases. Ann Pharmacotherrently being studied in animals might prove beneficial
32:459–470, 1998
in humans? 7. Cines DB, Pollak E, Buck CA, Loscalzo J, Zimmerman GA,
McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS,Dr. Goligorsky: As you’ve alluded to in your ques-
Barnathan ES, McCrae KR, Hug BA, Schmidt A-M, Sterntion, advanced glycosylation end products are involved
DM: Endothelial cell in physiology and in the pathophysiology
in the development of vascular complications of diabetes of vascular disorders. Blood 91:3527–3561, 1998
8. Ludmer PL, Selwyn AP, Shook LT, Wayne RR, Mudge GH,mellitus. Therefore, the search for pharmaceutical agents
Alexander RW, Ganz P: Paradoxical vasoconstriction inducedcapable of preventing their formation or degrading the
by acetylcholine in atherosclerotic coronary arteries. N Engl J
existing advanced glycosylation end products is continu- Med 315:1046–1051, 1986
9. Furchgott RF, Zawadzki JW: The obligatory role of endothelialing. Investigators at Columbia University in New York
cells in the relaxation of arterial smooth muscle by acetylcholine.are examining the therapeutic efficacy of a soluble recep-
Nature 288:373–376, 1980
tor for advanced glycosylation end products. In addition, 10. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous
modulator of leukocyte adhesion. Proc Natl Acad Sci USAaminoguanidine or its derivatives are being investigated,
88:4651–4655, 1991and the results of these studies are forthcoming.
11. De Caterina R, Libby P, Peng H, Thannickal V, Rajavashisth
Dr. King: In the setting of diseases that cause endothe- T, Gimbrone M, Shin W, Liao J: Nitric oxide decreases cytokine-
induced endothelial activation. J Clin Invest 96:60–68, 1995lial cell dysfunction, such as hypertension, do endothelial
12. Dubey R, Jackson E, Luscher TF: Nitric oxide inhibits angioten-cells lose morphologic appearance of the caveolae, or is
sin II-induced migration of rat aortic smooth muscle cells. J Clin
it just a functional change? Invest 96:141–149, 1995
13. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-Dr. Goligorsky: This is an area of active research,
bromo-cyclic guanosine monophosphate inhibit mitogenesis andbut no data have yet been reported. One should realize,
proliferation of cultured rat vascular smooth muscle cells. J Clin
however, that caveolae are dynamic structures that are Invest 83:1774–1777, 1989
14. Tsukahara H, Gordienko M, Gelato M, Goligorsky MS: Directcontinuously pinched off the plasma membrane and recy-
demonstration of the IGF-1-induced nitric oxide production bycled. It is not impossible that a simple static view obtain-
endothelial cells. Kidney Int 45:598–604, 1994
able by tissue sectioning for electron microscopy will be 15. Tsukahara H, Ende H, Magazine H, Bahou WF, Goligorsky
MS: Molecular and functional characterization of thenon-isopep-insufficient to disclose the entire spectrum of potential
tide-selective ETB receptor in endothelial cells: Receptor couplingchanges in disease processes. Hence, we hope that our
to nitric oxide synthase. J Biol Chem 269:21778–21785, 1994
caveolin-GFP construct will be valuable in solving this 16. Stefano G, Hartman A, Bilfinger T, Magazine H, Liu Y, Ca-
sares F, Goligorsky MS: Presence of the mu-3 opiate receptortype of problem using intravital microscopy.
in endothelial cells: Coupling to nitric oxide production and vaso-
dilation. J Biol Chem 270:30290–30293, 1995
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